Showing results (81-90 of 151) with videos related to

Sort By:
Pageof 16
Oncoimmunology|May 15, 2024
Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumorsDouglas C Chung, Maryam Ghaedi, Kathrin Warner, et al.
British Journal of Haematology|June 10, 2008
Clinical impact of HLA-DR15, a minor population of paroxysmal nocturnal haemoglobinuria-type cells, and an aplastic anaemia-associated autoantibody in children with acquired aplastic anaemiaNao Yoshida, Hiroshi Yagasaki, Yoshiyuki Takahashi, et al.
Biorxiv : the Preprint Server for Biology|May 3, 2023
Molecular, metabolic and functional CD4 T cell paralysis impedes tumor controlMengdi Guo, Diala Abd-Rabbo, Bruna Bertol, et al.
Cancer Medicine|March 3, 2020
Cancer patients' experiences with immune checkpoint modulators: A qualitative studyKari Ala-Leppilampi, Natalie A Baker, Chris McKillop, et al.
Cell Reports|August 31, 2023
Molecular, metabolic, and functional CD4 T cell paralysis in the lymph node impedes tumor controlMengdi Guo, Diala Abd-Rabbo, Bruna C Bertol, et al.
Cancers|July 24, 2021
Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint InhibitorsDeirdre Kelly, April A N Rose, Thiago Pimentel Muniz, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2021
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutationMichele Maio, Matteo S Carlino, Anthony M Joshua, et al.
Cancers|January 11, 2022
CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes MellitusThiago P Muniz, Daniel V Araujo, Kerry J Savage, et al.
Journal for Immunotherapy of Cancer|May 19, 2017
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapySacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 20, 2019
<i>TP53</i> mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analysesVictoria Mandilaras, Swati Garg, Michael Cabanero, et al.
Pageof 16